NEW YORK (GenomeWeb) – Biovica announced today that it has acquired cSens, expanding its portfolio of cancer diagnostic technologies. 

Uppsala, Sweden-based Biovica's core offering is DiviTum, a research-use-only ELISA-based biomarker assay that measures the activity of thymidine kinase (TK), an enzymatic biomarker associated with cancer cell proliferation and tumor aggressiveness, in serum or cell culture.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.